Condition: Multi-Drug Resistant Organism Colonization · Sponsor: Emory University
REACT is a phase two, open-label, randomized, controlled trial of microbiota therapy (MT) to reduce colonization with multi-drug resistant organisms (MDRO). REACT is designed to assess the safety and efficacy of MT administered to subjects colonized with a MDRO. The overarching hypothesis is that MT can reduce MDRO colonization with safety that is comparable to observation.
This description comes directly from the study's public registry record.
Deepti Suchindran, PhD · 404-727-9193 · deepti.rao.suchindran@emory.edu
Michael Woodworth, MD · michael.holmes.woodworth@emory.edu
Always discuss trial participation with your own doctor first.
| A.G Rhodes Wesley Woods | Atlanta, Georgia, United States | Recruiting |
| Emory Long Term Acute Care (LTAC) | Decatur, Georgia, United States | Recruiting |
| RML Specialty Hospital | Hinsdale, Illinois, United States | Recruiting |
| Penn Medicine Rittenhouse | Philadelphia, Pennsylvania, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06321536